# Physician/Patient Choice of Either High-Dose Recombinant Interferon Alfa-2B or Ipilimumab, Versus Pembrolizumab in Treating Patients With Stage III-IV High Risk Melanoma That Has Been Removed by Surgery

> clinical trial · VERIFIED · 2026-07-30

Status: ACTIVE_NOT_RECRUITING · Sponsor: National Cancer Institute (NCI) · Condition: Clinical Stage III Cutaneous Melanoma AJCC v8

- Company: National Cancer Institute (NCI)
- Sector: Clinical Stage III Cutaneous Melanoma AJCC v8
- Primary source: https://clinicaltrials.gov/study/NCT02506153

---
Source: MedFuel Intel news monitor. Verification tier: VERIFIED. Informational only, not investment advice. Corrections: media@medfuelinc.com.